GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » YoY EBITDA Growth

SciClone Pharmaceuticals (SciClone Pharmaceuticals) YoY EBITDA Growth : 101.71% (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. SciClone Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2017 was 101.71%.

SciClone Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2017 was $0.24.

SciClone Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for SciClone Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals YoY EBITDA Growth Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.66 52.66 100.78 14.09 10.15

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.17 -17.81 -41.53 46.77 101.71

SciClone Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

SciClone Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2016 is calculated as:

YoY EBITDA Growth (A: Dec. 2016 )
=(EBITDA per Share (A: Dec. 2016 )-EBITDA per Share (A: Dec. 2015 ))/ | EBITDA per Share (A: Dec. 2015 ) |
=(0.651-0.591)/ | 0.591 |
=10.15 %

SciClone Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2017 is calculated as:

YoY EBITDA Growth (Q: Jun. 2017 )
=(EBITDA per Share (Q: Jun. 2017 )-EBITDA per Share (Q: Jun. 2016 )) / | EBITDA per Share (Q: Jun. 2016 )) |
=(0.236-0.117)/ | 0.117 |
=101.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciClone Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » YoY EBITDA Growth
Comparable Companies
SZSE:300485 SZSE:300016 SZSE:000788 BOM:532872 XKRX:086450 SHSE:600351 HKSE:02552 XKRX:003850 SHSE:603079 BOM:530239 TSX:HEXO SHSE:603676 SHSE:600488 SZSE:002219 XKRX:000250 TSE:3341 HKSE:01349 SHSE:600594 SZSE:000915 SZSE:002412
Traded in Other Exchanges
N/A
Address
Website
http://www.sciclone.com
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480